We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Retinal detachment

27 January 2016 By Neil Unmack

The Swiss pharma group disappointed with earnings and forecasts. It’s a combination of drug patent pressure and challenges in its eyecare unit Alcon. Neither can be quickly fixed and more radical action seems off the table. A return to Novartis’ premium rating isn’t imminent. 

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)